Zenflow, Inc., a South San Francisco, CA-based medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), closed a $24m Series B financing round.
The round was led by Invus Opportunities with participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia Angels, CloudStone Capital, SV Tech Ventures, and others.
Led by Nick Damiano, Co-Founder and CEO, Zenflow is a medical device company dedicated to improving treatment for patients suffering from urinary obstruction caused by enlarged prostate.
Zenflow intends to use the funds for pivotal clinical trial and FDA clearance of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The company also announced the appointment of Susan Stimson as President. Ms. Stimson joins with over 25 years of experience in the development and commercialization of high-impact medical devices, most recently serving as Executive in Residence with KCK Group focusing on investment in commercial stage medical device companies. Prior to KCK, Ms. Stimson served as a founding team member of Intersect ENT, playing an instrumental role in the company’s evolution from R&D stage to a high-growth commercial business by building and leading a variety of its commercial and strategic functions from first product launch through the company’s initial public offering in 2014 and beyond as the company grew to more than $100 million in sales.